Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
Published: Friday, April 13, 2012 Last Updated: Friday, April 13, 2012
With the number of new drug applications (NDA) on the decline, a new approach that stops our dependence from old compounds, and utilizes the vast information available on protein interactions and structure, is desperately needed.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.